Efficacy and safety of ONO-4641 versus Interferon-β-1a in patients with multiple sclerosis
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Ceralifimod
Compared with
- Interferon beta-1a
Interferon alpha/beta receptor agonist
What it measured
Main measures
"Proportion of subjects free of qualifying relapse over at least 1 year (48 weeks).
Relapses
Other measures (1)
"• The qualifying Annual Relapse Rate over 2 years
Relapses
Who could take part
Relapsing MS
Inclusion: "For inclusion in the trial, all of the following inclusion criteria must be fulfilled: Exclusion: "A. Medical History and Concurrent Diseases
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective of this trial is to demonstrate the effect of ONO 4641 versus IFN β 1a (Avonex) 30 µg on the proportion of subjects, with RMS, who remain qualifying relapse–free during their participation in the trial when the last evaluable subject completes 1 year.
Loading reviews and guidelines…
Related trials
- VOYAGE
Phase 3 · Not yet recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
- IM047-050
Phase 3 · Recruiting
Still running
- COAST
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Br…
Phase 4 · Withdrawn
Stopped early
- A Study to Assess the Effectiveness and Safety of Ozanimo…
Phase 4 · Running, not recruiting
Still running
History
Started
Feb 2014
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error